作者: C A Jaffe , R DeMott-Friberg , A L Barkan
DOI: 10.1172/JCI118516
关键词: Hormone 、 Pharmacology 、 Growth hormone secretion 、 Growth hormone–releasing hormone 、 Somatostatin 、 Endogeny 、 Medicine 、 Internal medicine 、 Pyridostigmine 、 Endocrinology 、 Arginine 、 Antagonist
摘要: The roles of hypothalamic growth hormone-releasing hormone (GHRH) and somatostatin (SRIF) in pharmacologically stimulated (GH) secretion humans are unclear. GH responses could result either from GHRH release or acute decline SRIF secretion. To assess directly the role endogenous human secretion, we have used a competitive antagonist, (N-Ac-Tyr1,D-Arg2)GHRH(1-29)NH2 (GHRH-Ant), which previously shown is able to block response GHRH. We first tested whether an SRIF, independent action, would GH. Pretreatment with GHRH-Ant abolished exogenous (0.33 microgram/kg i.v.) but did not modify rise after termination infusion. then investigated pharmacologic stimuli release. arginine (30 g i.v. over 30 min), L-dopa (0.5 orally), insulin hypoglycemia (0.1 U/Kg i.v.), clonidine (0.25 mg pyridostigmine (60 orally) were measured healthy young men pretreatment saline 400 In every case, was significantly suppressed by GHRH-Ant. conclude that required for each these stimuli. Acute may be common mechanism compounds mediate